CellaVision and Beckman Coulter enhance partnership by adding EMEA to their global distribution agreement
(Thomson Reuters ONE) -
This information was released for public disclosure on April 8, 2013 at 8.25 am
CET.
CellaVision broadens cooperation with global leading manufacturer of biomedical
testing instrument systems Beckman Coulter by adding EMEA to their existing
global distribution agreement. The agreement gives Beckman Coulter a non-
exclusive right to sell CellaVision's products in hematology laboratories
worldwide, except Canada and Japan, from April 8, 2013*.
"We enhance the agreement with Beckman Coulter to also include the EMEA market.
Beckman Coulter provides us with a very strong sales channel and the ability to
continue increasing our market penetration in this region. Parallel sales
channels in most countries around the world is an important piece of our long
term strategy", says Yvonne Mårtensson, CEO of CellaVision.
Beckman Coulter and CellaVision have been developing their partnership since
2010, when they partnered in the USA, Latin America and Asia-Pacific, including
China and India. Hematology products covered in the agreement, such as the
CellaVision® DM96 and DM1200, are used by clinical laboratories for automated
medical microscopy analysis. Beckman Coulter can now offer their customers a
complete solution to help improve workflow efficiency, a requirement of many
mid-size and large size laboratories.
EMEA, especially Europe, is one of CellaVision's major growth markets. The
transition from manual microscopy to CellaVision's digital method has been
continually increasing over the years in the European countries. In 2012 Europe
accounted for 33 percent of the company's total sales, North America for 60
percent and Asia Pacific for 7 percent.
* In 2012 separate agreements were signed for Sweden, Norway and Denmark. These
agreements differ from the global distribution agreement in that CellaVision is
responsible for installation and support.
For further information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82 | Email: yvonne.martensson(at)cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other body
fluids in health care services. The products rationalize manual laboratory work,
and secure and support effective workflows and skills development within and
between hospitals. The company has leading-edge expertise in image analysis,
artificial intelligence and automated microscopy. In most countries sales are
via global partners. Products are sold directly in the Nordic countries and via
subsidiaries in the US, Canada and Japan. In 2012 sales were SEK 170 million and
sales continue to increase, with a growth target of at least 15 % per year over
an economic cycle. CellaVision's registered office is in Lund, Sweden. The share
is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at
www.cellavision.com.
Publication
This information is disclosed by CellaVision AB (publ) pursuant to the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public disclosure on April 8, 2013 at 8.25 am CET.
Press release as PDF:
http://hugin.info/132164/R/1690148/555090.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1690148]
Unternehmensinformation / Kurzprofil:
Datum: 08.04.2013 - 08:25 Uhr
Sprache: Deutsch
News-ID 246591
Anzahl Zeichen: 4145
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 157 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision and Beckman Coulter enhance partnership by adding EMEA to their global distribution agreement"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
